US Stock Movement | Latigo Biotherapeutics (LTGO.US) debuts on the US stock market with a share price increase of over 14% after the opening.

Zhitong Finance APP has learned that on Friday, non-opioid painkiller developer Latigo Biotherapeutics (LTGO.US) debuted on the U.S. stock market. As of the time of this report, the stock had risen over 14%, trading at $20.53. Latigo is focused on developing non-opioid pain medications targeting the Nav1.8 sodium ion channel. Its core candidate drug, LTG-001, is an oral Nav1.8 inhibitor primarily used for the treatment of moderate to severe acute pain, including postoperative pain. This medication aims to provide pain relief comparable to that of opioids while avoiding the risk of addiction. Nav1.8 is mainly expressed in peripheral pain-sensing neurons, and its inhibitors do not act on the central nervous system, therefore they are non-addictive.